New scan may reveal who will benefit from immunotherapy

NCT ID NCT03564197

Completed Diagnosis Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a new type of PET scan, which looks for a protein called PD-L1 on cancer cells, can predict how well patients with advanced lung cancer will respond to the immunotherapy drug nivolumab. Eighty patients received the scan before starting treatment. Researchers then tracked how long their cancer was controlled. The goal is to see if this imaging tool can help personalize treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-PD-L1 PET/CT scan (imaging tracer)
What this could lead to: If successful, this scan could help doctors identify which lung cancer patients are most likely to respond to immunotherapy, avoiding ineffective treatments.
What could go wrong: This is an early imaging study, not a treatment trial. The scan's accuracy may not be high enough to change clinical practice, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC STAGE IV

Contacts and locations

Locations

Antoni van Leeuwenhoek

Amsterdam, 1060CX, Netherlands
Antonius Ziekenhuis

Utrecht, Netherlands
Deventer Ziekenhuis

Deventer, Netherlands
Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands
LUMC

Leiden, Netherlands
MeanderMC

Amersfoort, Netherlands
Medisch Centrum Haaglanden

The Hague, Netherlands
VUmc

Amsterdam, 1007 MB, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.